Company profilePharmaceutical#484 of 1,318 in Pakistan✓ No DRAP alerts

AMGOMED PHARMA

Pharmaceutical company · 29 brands · 22 molecules

Ranked #23 of 44 companies in Antineoplastics

29 registered products 23 pharmaceutical brands 22 distinct molecules 0 DRAP alerts

Company overview

29
registered products
23
pharmaceutical brands
22
distinct molecules
6
therapeutic classes
0
DRAP alerts

AMGOMED PHARMA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 29 product registrations across 22 distinct molecules. Its portfolio is concentrated in Antineoplastics and Immunostimulants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by AMGOMED

7 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

6
ceilings with an approval date
4
not revised in 2+ years
2024
oldest approval year
20244
20262
Longest without revision

Top molecules by brand count

Paclitaxel4 brands
Oxaliplatin3 brands
Abiraterone3 brands
Doxorubicin2 brands
Leuprorelin2 brands
Filgrastim (Recombinant Human Granulocyte Colony-Stimulating Factor Injection2 brands
Irinotecan1 brand
Recombinant Human Interleukin-111 brand

Therapeutic classes

Antineoplastics · 3Immunostimulants · 2Drugs For Treatment Of Bone Diseases · 2Endocrine Hormone Therapy · 2Cancer · 1Antiemetics & Antinauseants · 1

Conditions treated

Oncology · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official21 products · Rs 3,435.61 – Rs 202,094.93
Servaid1 products · Rs 7,000 – Rs 7,000
Median across source: Rs 26,834.12

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Himmel Pharmaceuticals Private Limited holds 33 molecules not in this portfolio
AfatinibAfatinib DimaleateAlbuminBortezomibCaspofunginCisplatin
AJ Mirza Pharma Pvt Ltd holds 1 molecules not in this portfolio
Ciprofloxacin
AceclofenacBicalutamideBortezomibCarboplatinIrinotecan 20MgSevoflurane

Get the full profile for AMGOMED

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.